Table 1.
Patient Characteristics.
Figure 1.
Serum ferritin (A) and CRP (B) levels in HER2/neu-overexpressing patients before undergoing trastuzumab-containing therapy (n = 66).
The pretreatment values were moderately correlated (C).
Figure 2.
Serum ferritin and CRP predict response to trastuzumab-containing therapy.
Pre-treatment serum ferritin and CRP predict overall survival (A&C respectively) and progression-free survival (PFS; B&D respectively) in patients receiving trastuzumab-containing therapy. Low serum ferritin or CRP (<250 ng/ml and <7.25 mg/l respectively) had an overall better clinical outcome than high ferritin or CRP. Difference in OS and PFS were analyzed by Kaplan-Meier survival model with the median serum ferritin or CRP value as a cutoff point.
Table 2.
Serum ferritin and CRP levels in HER2/neu-overexpressing breast cancer patients (n = 66).
Figure 3.
Patients with elevation in both serum ferritin and CRP have the poorest response to trastuzumab-containing therapy.
Kaplan-Meier analysis of overall survival (A) and progression-free survival (B) in trastuzumab-treated patients stratified by their CRP and serum ferritin levels. High CRP (>7.25 mg/l); High Ferritin (>250 ng/ml).